Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, Oxygen consumption, Oxygen saturation
Clinical narrative: COVID-19 31Jan2023; COVID-19 31Jan2023; 5th dose: Moderna; This is a spontaneous report received from a Physician and a Consumer or other non HCP, Program ID.  A 64-year-old female patient received BNT162b2 (BNT162B2), on 26Feb2021 as dose 1, single (Lot number: EN6203), on 18Mar2021 as dose 2, single (Lot number: ER2613, Expiration Date: Jul2021), on 12Oct2021 as dose 3 (booster), single (Lot number: FF2587) and on 20Apr2022 as dose 4 (booster), single (Lot number: FF4984) at the age of 63 years, all intramuscular for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 24Sep2022 as dose 5 (booster), single (Lot number: AS7143C) intramuscular for covid-19 immunisation. The patient's relevant medical history included: "COPD" (unspecified if ongoing), notes: intermittent O2 use; "Asthma" (unspecified if ongoing); "slightly blood pressure" (unspecified if ongoing); "Patient has past hx of etoh use disorder/alcohol use disorder" (unspecified if ongoing), notes: sober for 8 years; "Active smoking of cigarettes/Long term smoking" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 24Sep2022, outcome "recovered", described as "5th dose: Moderna "; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 31Jan2023, outcome "recovered" and all described as "COVID-19 31Jan2023". The patient underwent the following laboratory tests and procedures: Oxygen consumption: (unspecified date) 2, notes: units: L/min n.c; Oxygen saturation: (unspecified date) <90 %; SARS-CoV-2 test: (31Jan2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid from 01Feb2023 for 5 days. Clinical course: This physician reported for a 65-Year old female patient in response to the HCP letter sent via email. They were a retired family physician and continued to do part-time public health. (Name withheld) was their sister. She got her regular medical care through her primary care provider and pulmonologist. They did not provide usual medical care to her bet did call in 5day courses of Paxlovid for each of her 3 episodes of COVID-19. In each instance she was unable to get through the telephone triage system of her providers in a timely fashion, and therefore they called in the prescription for Paxlovid. She had received 7 doses of MRNA COVID-19 vaccine (6/7 one Pfizer). In spite of this she had experienced COVID-19 on 3 separate occasions (diagnosed with federally mailed RAT tests). She took extensive precaution during the pandemic including remaining at home, limiting visits to occasional visits by her children & grand children, and use of N95 masks. Her illnesses occurred after minimal or unknown exposure. It seemed likely that her immunological protection was lacking. This may be secondary to her past alcohol use disorder (she had been sober for 8 years), her long term smoking history, and her COPD. However, it seemed likely that vaccination may have provided some level of protection from progression to more severe disease such as hospitalization, in conjunction with timely initiation of treatment with Paxlovid. The patient stated COPD (Chronic obstructive pulmonary disease)/ asthma (medical history) and every time she got COVID it affected her lungs, it made her out of breath. She couldn't imagine what it would be like without the Paxlovid. Patient stated to have slight blood pressure.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400096881 same patient/product, different dose;